Christophe Sajous

IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer

Margaux Hubert, Élisa Gobbini, Coline Couillault et al. · Science Immunology · 2020 · 142 citations

Medicine, Immunology, Oncology +17

A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory <i>BRAF</i> p.V600E-Mutated Differentiated Thyroid Cancer

Sophie Leboulleux, Christine Do Cao, Slimane Zerdoud et al. · Clinical Cancer Research · 2023 · 94 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Surgical Margins and Adjuvant Therapies in Malignant Phyllodes Tumors of the Breast: A Multicenter Retrospective Study

Mathias Neron, Christophe Sajous, Simon Thézenas et al. · Annals of Surgical Oncology · 2020 · 66 citations

Medicine, Oncology, Surgery +17

Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7)

Olivier Colomban, Michel Tod, Julien Péron et al. · JNCI Cancer Spectrum · 2020 · 44 citations · Full text

Medicine, Oncology, Pharmacology +15

MERAIODE: A Redifferentiation Phase II Trial With Trametinib and Dabrafenib Followed by Radioactive Iodine Administration for Metastatic Radioactive Iodine Refractory Differentiated Thyroid Cancer Patients With a BRAFV600E Mutation (NCT 03244956)

Sophie Leboulleux, Christine Do Cao, Slimane Zerdoud et al. · Journal of the Endocrine Society · 2021 · 30 citations · Full text

Medicine, Oncology, Pharmacotherapy +16